Dr. Weeks Comment: Hypothermia, as an effective treatment for people with cancer, was pioneered in Philadelphia by world-famous neurosurgeon Dr. Temple Fay, M.D.
Out of his inspired work arose the entire modern field of hypotheramia in medicine :
Now we have current research demonstrating the benefits of hyperthermia.
So which is it. “Chill out” or “get fired up” to kill cancer?
The answer is both, and the reason is instructive: the host (you) is always more adaptive than the infecting pathological agent (cancer, bacteria) because you are a generalist and a pathological cell is a specialist. The cancer cell (more properly, a cell taken over by cancer) has forfeited its options and has only one goal: to avoid apoptosis (natural programmed cell death). As a specialist, it has more stringent requirements: more sugar, less oxygen, and narrower ranges of temperature for its tenuous existence.
Recall the curative effect of a fever, which the immune system of your child created to fight the bacterial or viral infection. Yes, we parents worry about excessive fever ( seizure, neurological damage) but also we know that there is wisdom in that fever and that, whereas the child will survive the fever, the bacteria won’t! It is the same situation with a cancer: shift the human physiology out of its comfort zone and the human survives whereas the pathological cells (those full of cancer or those infected with bacteria, viri or parasites) are far more vulnerable. In this hyper or hypo state, conventional drugs are more effective. This is why insulin potentitated treatments are effective for malaria, Lymes disease and cancer. See
Here following is a great article on hyperthermia.
Sunday, 15 November 2009
There was another victory for the use of regional deep hyperthermia in the treatment of cancer. The latest victory occurred in the treatment of high-risk bladder cancer. Heat treatment, delivered via the BSD 2000 machine, improved such patients’ five-year survival rate from 67 to 80 percent. The local tumor control rate went from 63 to 81 percent. In addition, the disease-specific survival was 88 percent, metastasis-free survival was 89 percent, and the bladder-preserving rate was 96 percent at three years.
The median number of weekly hyperthermia treatments that patients received was five (with a range of 1-7). So some of the patients received just a single hyperthermia treatment, yet their results were averaged with the rest. Not surprisingly, there was a correlation between the number of hyperthermia treatments patients received and their overall survival rate -simply put, those who received more frequent treatments did better (Wittlinger 2009).
The study was published in Radiotherapy and Oncology by Dr. Michael Wittlinger of the Department of Radiation Oncology at Erlangen University Medical School in Germany and seven colleagues. Radiotherapy and Oncology is the official publication of the European Society for Therapeutic Radiology and Oncology.
Other Studies Show the Same Effect
This is not the only study to demonstrate improved results when hyperthermia is added to conventional treatment for bladder cancer. Thus, Renzo Columbo, MD, of Milan, Italy, reported on a multi-center trial in which 83 patients with intermediate or high-risk bladder tumors who were randomized to receive either the drug mitomycin-C alone or the same drug plus hyperthermia (following bladder-sparing surgery). The recurrence rate for those receiving mitomycin C alone was 57.5 percent, but it plummeted to 17.1 percent in those who also received hyperthermia. That study appeared in the Journal of Clinical Oncology (Colombo 2003).
In addition, Jacoba van der Zee, MD, and colleagues at the Erasmus Medical Center in Holland reported on a prospective, randomized trial that included 101 bladder cancer patients. The addition of hyperthermia to radiotherapy significantly increased the complete tumor response rate (the disappearance of all local tumor) from 51 percent for those treated with radiotherapy alone to 73 percent in patients also treated with hyperthermia, a 22 percent improvement. The duration of local control was also significantly longer. That study was published in the Lancet (van der Zee 2000).
For the record, the same trial also included patients with cervical or rectal cancer patients. The treatment worked in all cancer types, but the response was even greater in cervical cancer, where hyperthermia increased the complete response (CR) rate from 57 to 83 percent, a 26 percent difference. The three-year survival rate went from 27 to 51 percent (Van der Zee 2000). As I reported in my newsletter of June 15, 2009, hyperthermia has now become part of standard treatment for cervical cancer in Holland and has been recommended as such by the German Cancer Society (Frankena 2008 and Frankena 2009). By contrast, the device used in the latest German trial, the BSD 2000, although made in the United States, is restricted to investigational use by the Food and Drug Administration (FDA).
The accumulating data on the benefits of hyperthermia gives the lie to the idea that American oncologists will adopt any therapeutic measure, provided that it is proven effective in clinical trials. In my opinion, a great many American patients will die needlessly before the cancer establishment wakes up to the fact that hyperthermia is a relatively harmless way of prolonging the lives of many cancer patients.
–Ralph W. Moss, Ph.D.
Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol. 2003;21:4270-4276.
Franckena M, Stalpers LJ, Koper PC, et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008;70:1176-1182.
Franckena M, Lutgens LC, Koper PC, et al. Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients. Int J Radiat Oncol Biol Phys. 2009;73:242-250.
Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol. 2001;52:273-278.
Wittlinger M, Rödel CM, Weiss C, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93:358-363.